Latest / Raleigh News Today | 2 Min News | The Daily News Now!
JPMorgan Sees Nuvation Bio Stock Double | Raleigh News
JPMorgan just slapped an “Overweight” rating on Nuvation Bio, predicting its stock could double to $13 by December 2027, fueled by blockbuster lung cancer drug IBTROZI—already the top choice for new patients and driving record-breaking Q2 revenue of $31.7M, despite an $0.18 loss per share. With safusidenib in the pipeline and a historically undervalued price-to-sales ratio, the bank sees massive upside—if the biotech can keep its momentum and avoid the pitfalls of small-cap drugmakers. High risk, high reward. Listen in comfort:Get a discount on a Soli Pillow…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.